Coherus Net Income From Continuing Ops from 2010 to 2025
| CHRS Stock | USD 0.84 0.01 1.18% |
Net Income From Continuing Ops | First Reported 2012-12-31 | Previous Quarter -10.8 M | Current Value -50.7 M | Quarterly Volatility 81.1 M |
Check Coherus BioSciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Coherus BioSciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.5 M, Interest Expense of 16.9 M or Selling General Administrative of 106.6 M, as well as many indicators such as Price To Sales Ratio of 0.56, Dividend Yield of 0.0 or Days Sales Outstanding of 93.4. Coherus financial statements analysis is a perfect complement when working with Coherus BioSciences Valuation or Volatility modules.
Coherus | Net Income From Continuing Ops |
Latest Coherus BioSciences' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Coherus BioSciences over the last few years. It is Coherus BioSciences' Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Coherus BioSciences' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Coherus Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (110,720,978) | |
| Geometric Mean | 118,202,990 | |
| Coefficient Of Variation | (118.99) | |
| Mean Deviation | 105,140,019 | |
| Median | (87,177,000) | |
| Standard Deviation | 131,749,708 | |
| Sample Variance | 17358T | |
| Range | 424M | |
| R-Value | 0.04 | |
| Mean Square Error | 18562.1T | |
| R-Squared | 0 | |
| Significance | 0.87 | |
| Slope | 1,212,740 | |
| Total Sum of Squares | 260369.8T |
Coherus Net Income From Continuing Ops History
About Coherus BioSciences Financial Statements
Coherus BioSciences shareholders use historical fundamental indicators, such as Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Coherus BioSciences investors may analyze each financial statement separately, they are all interrelated. The changes in Coherus BioSciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Coherus BioSciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 28.5 M | 29.9 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.